EGFR and neoplasm: In parallel, NCT04976218 specifies a phase I trial to evaluate CAR-EGFR-TGFR-KO T cells engineered through CRISPR/Cas9 to target TGF-β receptor II in previously treated EGFR-positive tumor cells (262).